Indication and Usage

Daily administration of Pulmozyme^® (dornase alfa) Inhalation Solution along with standard therapies is indicated in the management of cystic fibrosis patients to improve lung function. In patients with a forced vital capacity (volume of air exhaled with maximum effort and speed) greater than or equal to 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring the administration of injectable antibiotics.

In our pivotal study, safety and efficacy of daily administration has not been studied in patients beyond 12 months.

Important Safety Information

Pulmozyme should not be used in patients who are allergic to any of its ingredients. Pulmozyme should be used along with standard therapies for cystic fibrosis.
When starting Pulmozyme therapy, patients may experience change in or loss of their voice, discomfort in the throat, chest pain, red watery eyes, rash, dizziness, fever, or runny nose.
These side effects are usually mild and short-lived.

For further information, please see the Pulmozyme full Prescribing Information. If you have questions, please discuss them with your CF healthcare team.

Genentech Access to Care Foundation

Financial Support

Visit CF Living
This online community is a place for CF patients and caregivers to get advice, share stories and learn about others fighting this disease.

The Genentech^® Access to Care Foundation was established to help qualified patients with unmet medical needs receive proper medical treatment. This resource may be available to help those who are not able to obtain Pulmozyme for financial reasons.

If you have no insurance, or you are effectively uninsured because your health insurance plan denies you access to Pulmozyme, you can apply to the Genentech Access to Care Foundation for help with your treatment.

Contact Genentech Access to Care Foundation to learn more. Information is available at www.PulmozymeAccessSolutions.com or at 1-866-681-3329.